Early-onset endothelin receptor blockade in hypertensive heterozygous Ren-2 rats

Vascular Pharmacology

Volumn 45, Issue 3, 2006, Pages 163-170

  Vaněčková, Ivana ^a,b   Kramer, Herbert J ^c   Bäcker, Angela ^c   Schejbalová, Stanislava ^a,b   Vernerová, Zdena ^a,d   Eis, Václav ^a,d   Opočenský, Martin ^a,b   Dvořák, Pavel ^a,b   Červenka, Luděk ^a,b  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^b Ctr for Exp Cardiovasc Research   (Czech Republic)

^c UNIVERSITY OF BONN   (Germany)

^d CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Atrasentan; Bosentan; End organ damage; Endothelin receptors; Ren 2 rats

Indexed keywords

ATRASENTAN; BOSENTAN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; ENDOTHELIN B RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; GLOMERULOSCLEROSIS; HEART HYPERTROPHY; HEART LEFT VENTRICLE; HETEROZYGOSITY; HYPERTENSION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; RAT STRAIN; STATISTICAL SIGNIFICANCE; SURVIVAL RATE;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BODY WEIGHT; CARDIOMEGALY; DISEASE MODELS, ANIMAL; ENDOTHELIN-1; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HETEROZYGOTE; HYPERTENSION; MALE; PROTEINURIA; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; RECEPTORS, ENDOTHELIN; RENIN; SODIUM CHLORIDE, DIETARY; SULFONAMIDES; TIME FACTORS;

EID: 33750841750     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2006.05.003     Document Type: Article

References (41)

1. Allcock G.H., Venema R.C., and Pollock D.M. ETA receptor blockade attenuates the hypertension but not renal dysfunction in DOCA-salt rats. Am. J. Physiol. 275 (1998) R245-R252
2. Barton M., d'Uscio L.V., Shaw S., Meyer P., Moreau P., and Luscher T.F. ET(A) receptor blockade prevents increased tissue endothelin-1, vascular hypertrophy, and endothelial dysfunction in salt-sensitive hypertension. Hypertension 31 (1998) 499-504
3. Blezer E.L., Nicolay K., Goldschmeding R., Jansen G.H., Koomans H.A., Rabelink T.J., and Joles J.A. Early-onset but not late-onset endothelin-A-receptor blockade can modulate hypertension, cerebral edema, and proteinuria in stroke-prone hypertensive rats. Hypertension 33 (1999) 137-144
4. Bohlender J., Gerbaulet S., Kramer J., Gross M., Kirchengast M., and Dietz R. Synergistic effects of AT(1) and ET(A) receptor blockade in a transgenic, angiotensin II-dependent, rat model. Hypertension 35 (2000) 992-997
5. Callahan M.F., Li P., Ferrario C.M., Ganten D., and Morris M. Salt-sensitive hypertension in (mREN-2)27 transgenic rats. Hypertension 27 (1996) 573-577
6. Dahl L.K., Knudsen K.D., Heine M.A., and Leitl G.J. Effects of chronic excess salt ingestion. Modification of experimental hypertension in the rat by variations in the diet. Circ. Res. 22 (1968) 11-18
7. D'Angelo G., Pollock J.S., and Pollock D.M. Endogenous endothelin attenuates the pressor response to acute environmental stress via the ETA receptor. Am. J. Physiol. Heart Circ. Physiol. 288 (2005) H1829-H1835
8. de Nucci G., Gryglewski R.J., Warner T.D., and Vane J.R. Receptor-mediated release of endothelium-derived relaxing factor and prostacyclin from bovine aortic endothelial cells is coupled. Proc. Natl. Acad. Sci. U. S. A. 85 (1988) 2334-2338
9. Dvorak P., Kramer H.J., Backer A., Maly J., Kopkan L., Vaneckova I., Vernerova Z., Opocensky M., Tesar V., Bader M., Ganten D., Janda J., and Cervenka L. Blockade of endothelin receptors attenuates end-organ damage in homozygous hypertensive ren-2 transgenic rats. Kidney Blood Press Res. 27 (2004) 248-258
10. Ehmke H., Faulhaber J., Munter K., Kirchengast M., and Wiesner R.J. Chronic ETA receptor blockade attenuates cardiac hypertrophy independently of blood pressure effects in renovascular hypertensive rats. Hypertension 33 (1999) 954-960
11. Elmarakby A.A., Dabbs L.E., Pollock J.S., and Pollock D.M. ETA receptor blockade attenuates hypertension and decreases reactive oxygen species in ETB receptor-deficient rats. J. Cardiovasc. Pharmacol. 44 (2004) S7-S10
12. Gardiner S.M., March J.E., Kemp P.A., and Bennett T. Cardiovascular effects of endothelin-1 and endothelin antagonists in conscious, hypertensive ((mRen-2)27) rats. Br. J. Pharmacol. 131 (2000) 1732-1738
13. Gariepy C.E., Ohuchi T., Williams S.C., Richardson J.A., and Yanagisawa M. Salt-sensitive hypertension in endothelin-B receptor-deficient rats. J. Clin. Invest. 105 (2000) 925-933
14. Gellai M., Fletcher T., Pullen M., and Nambi P. Evidence for the existence of endothelin-B receptor subtypes and their physiological roles in the rat. Am. J. Physiol. 271 (1996) R254-R261
15. Hirata Y., Takagi Y., Fukuda Y., and Marumo F. Endothelin is a potent mitogen for rat vascular smooth muscle cells. Atherosclerosis 78 (1989) 225-228
16. Inscho E.W., Imig J.D., Cook A.K., and Pollock D.M. ET(A) and ET(B) receptors differentially modulate afferent and efferent arteriolar responses to endothelin. Br. J. Pharmacol. 146 (2005) 1019-1026
17. Just A., Olson A.J., and Arendshorst W.J. Dual constrictor and dilator actions of ET(B) receptors in the rat renal microcirculation: interactions with ET(A) receptors. Am. J. Physiol., Renal Physiol. 286 (2004) F660-F668
18. Kenyon K.W., and Nappi J.M. Bosentan for the treatment of pulmonary arterial hypertension. Ann. Pharmacother. 37 (2003) 1055-1062
19. Konishi F., Okada Y., Takaoka M., Gariepy C.E., Yanagisawa M., and Matsumura Y. Role of endothelin ET(B) receptors in the renal hemodynamic and excretory responses to big endothelin-1. Eur. J. Pharmacol. 451 (2002) 177-184
20. Masaki T. Historical review: endothelin. Trends Pharmacol. Sci. 25 (2004) 219-224
21. Moreau P., and Schiffrin E.L. Role of endothelins in animal models of hypertension: focus on cardiovascular protection. Can. J. Physiol. Pharm. 81 (2003) 511-521
22. Mulder P., Boujedaini H., Richard V., Derumeaux G., Henry J.P., Renet S., Wessale J., Opgenorth T., and Thuillez C. Selective endothelin-a versus combined endothelin-A/endothelin-B receptor blockade in rat chronic heart failure. Circulation 102 (2000) 491-493
23. Mullins J.J., Peters J., and Ganten D. Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature 344 (1990) 541-544
24. Nelson J.B. Endothelin inhibition: novel therapy for prostate cancer. J. Urol. 170 (2003) S65-S67
25. Ohkita M., Wang Y., Nguyen N.D., Tsai Y.H., Williams S.C., Wiseman R.C., Killen P.D., Li S., Yanagisawa M., and Gariepy C.E. Extrarenal ETB plays a significant role in controlling cardiovascular responses to high dietary sodium in rats. Hypertension 45 (2005) 940-946
26. Opgenorth T.J., Adler A.L., Calzadilla S.V., Chiou W.J., Dayton B.D., Dixon D.B., Gehrke L.J., Hernandez L., Magnuson S.R., Marsh K.C., Novosad E.I., von Geldern T.W., Wessale J.L., Winn M., and Wu-Wong J.R. Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist. J. Pharmacol. Exp. Ther. 276 (1996) 473-481
27. Opocensky M., Dvorak P., Maly J., Kramer H.J., Backer A., Kopkan L., Vernerova Z., Tesar V., Zima T., Bader M., Ganten D., Janda J., and Vaneckova I. Chronic endothelin receptor blockade reduces end-organ damage independently of blood pressure effects in salt-loaded heterozygous Ren-2 transgenic rats. Physiol. Res. 53 (2004) 581-593
28. Opocensky, M., Kramer, H.J., Backer, A., Vernerova, Z., Eis, V., Cervenka, L., Certikova Chabova, V., Teasr, V., Vaneckova, I., submitted for publication. Late onset endothelin-A receptor blockade substantially improves survival rate in homozygous hypertensive Ren-2 Rats. Hypertension.
29. Ortmann J., Amann K., Brandes R.P., Kretzler M., Munter K., Parekh N., Traupe T., Lange M., Lattmann T., and Barton M. Role of podocytes for reversal of glomerulosclerosis and proteinuria in the aging kidney after endothelin inhibition. Hypertension 44 (2004) 974-981
30. Rossi G.P., Sacchetto A., Rizzoni D., Bova S., Porteri E., Mazzocchi G., Belloni A.S., Bahcelioglu M., Nussdorfer G.G., and Pessina A.C. Blockade of angiotensin II type 1 receptor and not of endothelin receptor prevents hypertension and cardiovascular disease in transgenic (mREN2)27 rats via adrenocortical steroid-independent mechanisms. Arterioscler. Thromb. Vasc. Biol. 20 (2000) 949-956
31. Rothermund L., Kossmehl P., Neumayer H.H., Paul M., and Kreutz R. Renal damage is not improved by blockade of endothelin receptors in primary renin-dependent hypertension. J. Hypertens. 21 (2003) 2389-2397
32. Rothermund L., Traupe T., Dieterich M., Kossmehl P., Yagil C., Yagil Y., and Kreutz R. Nephroprotective effects of the endothelin ET(A) receptor antagonist darusentan in salt-sensitive genetic hypertension. Eur. J. Pharmacol. 468 (2003) 209-216
33. Roux S., Breu V., Ertel S.I., and Clozel M. Endothelin antagonism with bosentan: a review of potential applications. J. Mol. Med. 77 (1999) 364-376
34. Saam T., Ehmke H., Haas C., Ritz E., and Amann K. Effect of endothelin blockade on early cardiovascular remodeling in the one-clip-two-kidney hypertension of the rat. Kidney Blood Press Res. 26 (2003) 325-332
35. Salani D., Rosano L., Di C., Spinella V., Venuti F., Padley A., Nicotra R.J., Natali M.R., and Bagnato P.G. ABT-627, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma growth in vitro. Clin. Sci. (Lond.) 103 Suppl 48 (2002) 318S-321S
36. Vaneckova I., Kramer H.J., Backer A., Vernerova Z., Opocensky M., and Cervenka L. Early endothelin-A receptor blockade decreases blood pressure and ameliorates end-organ damage in homozygous Ren-2 rats. Hypertension 46 part 2 (2005) 969-974
37. Weinberger M.H. Salt sensitivity: does it play an important role in the pathogenesis and treatment of hypertension?. Curr. Opin. Nephrol. Hypertens. 5 (1996) 205-208
38. Whitworth C.E., Veniant M.M., Firth J.D., Cumming A.D., and Mullins J.J. Endothelin in the kidney in malignant phase hypertension. Hypertension 26 (1995) 925-931
39. Yagil C., Sapojnikov M., Katni G., Ilan Z., Zangen S.W., Rosenmann E., and Yagil Y. Proteinuria and glomerulosclerosis in the Sabra genetic rat model of salt susceptibility. Physiol. Genomics 9 (2002) 167-178
40. Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., Yazaki Y., Goto K., and Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332 (1988) 411-415
41. Zicha J., and Kunes J. Ontogenetic aspects of hypertension development: analysis in the rat. Physiol. Rev. 79 (1999) 1227-1282